Neurocrine Biosciences (NBIX) Amortization of Deferred Charges (2017 - 2026)
Neurocrine Biosciences (NBIX) posted Amortization of Deferred Charges of $2.7 million for Q1 2026, down 59.09% on a QoQ basis from $6.6 million in Q3 2025, and down 62.5% year-over-year from $7.2 million in Q1 2025.
Neurocrine Biosciences (NBIX) Amortization of Deferred Charges (2017 - 2026) Analysis & Trends
Neurocrine Biosciences' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- Quarterly Amortization of Deferred Charges fell 62.5% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.6 million (up 202.56% YoY) and the FY2023 annual result came in at $700000.0, down 41.67% from the prior year.
- Amortization of Deferred Charges was $2.7 million for Q1 2026 at Neurocrine Biosciences, down from $6.6 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $7.2 million in Q1 2025 and bottomed at $100000.0 in Q4 2023.
- A 5-year average of $2.0 million and a median of $300000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2025 — Amortization of Deferred Charges soared 2100.0% — and 2026, when it plunged 62.5%.
- Neurocrine Biosciences' Amortization of Deferred Charges stood at $200000.0 in 2022, then plunged by 50.0% to $100000.0 in 2023, then jumped by 200.0% to $300000.0 in 2024, then surged by 2100.0% to $6.6 million in 2025, then sank by 59.09% to $2.7 million in 2026.
- Business Quant data shows NBIX's Amortization of Deferred Charges at $2.7 million in Q1 2026, $6.6 million in Q3 2025, and $7.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.19 Bn | 87.33 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn |
| 3 | Zoetis | 32.52 Bn | 30.58 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.22 Bn | 21.07 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - |
| 7 | Viatris | 20.29 Bn | 18.48 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.59 Bn | 12.16 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.70 Mn |
| Mar 31, 2026 | 2.70 Mn |
| Sep 30, 2025 | 6.60 Mn |
| Sep 30, 2025 | 6.60 Mn |
| Jun 30, 2025 | 7.10 Mn |
| Jun 30, 2025 | 7.10 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 200,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Dec 31, 2022 | 200,000.00 |
| Dec 31, 2022 | 200,000.00 |